1070764-29-2

Upstream product

• 1070764-09-8 (1S,2R,3R,4S)-3,4-bis(hydroxymethyl)-2-(2-methylphenyl)cyclohexanol 
• 1070764-13-4 (3aR,4R,5S,7aS)-2-benzyl-5-hydroxy-4-(2-methylphenyl)octahydro-1H-isoindole 
• 1070764-21-4 tert-butyl (3aR,4R,5S,7aS)-5-{1-[3,5-bis(trifluoromethyl)phenyl]-2-ethoxy-2-oxoethoxy}-4-(2-methylphenyl)-octahydro-2H-isoindole-2-carboxylate 
• 1070763-61-9 tert-butyl (3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)-phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindole-2-carboxylate 
• 1070764-23-6 tert-butyl (3aR,4R,5S,7aS)-5-{(1S)-2-(benzoyloxy)-1-[3,5-bis-(trifluoromethyl)phenyl]ethoxy}-4-(2-methylphenyl)-octahydro-2H-isoindole-2-carboxylate 
• 1070764-11-2 [(1S,2R,3R,4S)-4-hydroxy-3-(2-methylphenyl)cyclohexane-1,2-diyl]bis(methylene)dipropane-1-sulfonate 
• 1070764-15-6 tert-butyl (3aR,4R,5S,7aS)-5-hydroxy-4-(2-methylphenyl)octahydro-2H-isoindole-2-carboxylate 
• 918417-38-6 diethyl (1S,2S,3R,4S)-4-hydroxy-3-(2-methylphenyl)cyclohexane-1,2-dicarboxylate 
• 1070764-02-1 triethyl{[1-(2-methylbenzylidene)prop-2-en-1-yl]oxy}silane 
• 98-88-4 benzoyl chloride 
• 1070764-25-8 (2S)-2-[3,5-bis(trifluoromethyl)phenyl]-2-{[(3aR,4R,5S,7aS)-4-(2-methylphenyl)octahydro-1H-isoindol-5-yl]oxy}ethyl benzoate 
• 1070764-28-1 (2S)-2-[3,5-bis(trifluoromethyl)phenyl]-2-{[(3aR,4R,5S,7aS)-2-{[(chloroacetyl)amino]carbonyl}-4-(2-methylphenyl)-octahydro-1H-isoindol-5-yl]oxy}ethyl benzoate 

Downstream Products

• 1070763-58-4 2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one 

Relevant academic research and scientific papers

2-[(3a R,4 R,5 S,7a S)-5-{(1 S)-1-[3,5-bis(trifluoromethyl)phenyl]-2- hydroxyethoxy}-4-(2-methylphenyl)octahydro-2 H -isoindol-2-yl]-1,3-oxazol-4(5 H)-one: A potent human NK1 receptor antagonist with multiple clearance pathways

Hydroisoindoline 2 has been previously identified as a potent, brain-penetrant NK1 receptor antagonist with a long duration of action and improved profile of CYP3A4 inhibition and induction compared to aprepitant. However, compound 2 is predict

HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.